Please login to the form below

Not currently logged in
Email:
Password:

J&J back in frame to buy Actelion after Sanofi talks break down

Parties now in exclusive negotiations about a possible deal

Johnson and Johnson logoTalks between Actelion and Sanofi over a possible takeover have broken down, and the Swiss biotech is back at the table with previously spurned Johnson & Johnson.

J&J confirmed in a short statement that it was talking with Actelion once again, and this time said it is in 'exclusive' negotiations about a possible deal. As before, all parties are taking pains to stress that there is no guarantee that an agreement will be reached.

J&J and Actelion insisted they will say no more on the matter until 'it is appropriate to do so, or a formal agreement has been reached', and Sanofi is also keeping silent. News of the volte-face came just a week after Actelion said it had abandoned talks with J&J, and mere hours after reports were emerging of an imminent deal with the French pharma major.

At the time, J&J's offer - estimated at around 250 Swiss francs per share which would value Actelion at around $26bn - was reportedly turned down as being too low. There were also suggestions that Actelion chief executive Jean-Paul Clozel was pushing for a say in the development of certain pipeline assets.

According to a Bloomberg report citing unnamed sources, Sanofi had proffered a sweetened deal -including $20 per share in the form of contingent voting rights (CVRs) - that would have given Actelion shareholders a further return on top of the purchase price if Actelion's pipeline delivers as promised.  

Actelion has been through a difficult patch after losing patent protection for pulmonary artery hypertension (PAH) blockbuster Tracleer (bosentan), but is on the up with strong growth for follow-up PAH drugs Opsumit (macitentan) and Uptravi (selexipag. 

The two new drugs are predicted to bring in combined sales of $4bn-plus by 2020, and Actelion also has some pipeline candidates in which Clozel has great confidence -including ponesimod for multiple sclerosis, an insomnia candidate and early-stage projects for cardiovascular and inflammatory disorders.

Actelion shares rose sharply yesterday as reports involving both Sanofi and J&J emerged. Shares in Sanofi were however largely unchanged in the wake of the Actelion and J&J announcement - possibly reflecting investors' concerns that Actelion could prove an expensive purchase for the French pharma major.

Buying Actelion could give J&J some near-term growth products to boost its sales as it faces biosimilar competition to blockbuster immunology therapy Remicade (infliximab), which generated $6.6bn in sales last year.

Article by
Phil Taylor

22nd December 2016

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ashfield

Reaching your audiences, wherever they are. Ashfield is an international provider of outsourcing solutions to the pharmaceutical industry, dedicated to...

Latest intelligence

How to create a multi-channel marketing strategy and plan
You know what it is and why you need one, now find out how to create a successful pharma multi-channel marketing strategy and plan...
Biosimilars: Getting the flock to market
The biosimilars field is about to become very crowded. Here are some Life tips on how to stand out from the herd...
Creative effectiveness: how to achieve tangible results
Chris Field, Director and Head of Creative Services at Blue Latitude Health, reveals what it takes to create winning creative campaigns that achieve results in the Pharma market....

Infographics